Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q38070436)
Watch
English
Cutaneous toxicities of RAF inhibitors.
scientific article published on January 2013
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23276366
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 February 2020
review article
1 reference
stated in
Europe PubMed Central
title
Cutaneous toxicities of RAF inhibitors
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23276366
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 February 2020
main subject
dabrafenib
1 reference
stated in
ChEBI release 2020-05-28
ChEBI ID
75045
author
Pablo Fernandez-Peñas
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23276366
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 February 2020
Georgina V. Long
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23276366
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 February 2020
author name string
Rachael Anforth
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23276366
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 February 2020
publication date
1 January 2013
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23276366
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 February 2020
published in
Lancet Oncology Commission
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23276366
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 February 2020
volume
14
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23276366
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 February 2020
issue
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23276366
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 February 2020
page(s)
e11-8
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23276366
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 February 2020
cites work
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
NRAS mutation status is an independent prognostic factor in metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improving melanoma classification by integrating genetic and morphologic features
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Targeting cancer with small molecule kinase inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
BRAF targeted therapy changes the treatment paradigm in melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase II trial of sorafenib in metastatic melanoma with tissue correlates
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
BRAF as therapeutic target in melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dermatologic symptoms associated with the multikinase inhibitor sorafenib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Meta-analysis of dermatological toxicities associated with sorafenib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vemurafenib in melanoma with BRAF V600E mutation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ultraviolet A and photosensitivity during vemurafenib therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activation of Akt by mechanical stretching in human epidermal keratinocytes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970413-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1470-2045(12)70413-8
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23276366
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 February 2020
PubMed publication ID
23276366
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23276366
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23276366%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 February 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit